Latest SILVERARC CAPITAL MANAGEMENT, LLC Stock Portfolio

SILVERARC CAPITAL MANAGEMENT, LLC Performance:

2025 Q4: 20.75%YTD: 53.51%2024: 13.48%

Performance for 2025 Q4 is 20.75%, and YTD is 53.51%, and 2024 is 13.48%.

About SILVERARC CAPITAL MANAGEMENT, LLC and 13F Hedge Fund Stock Holdings

SILVERARC CAPITAL MANAGEMENT, LLC is a hedge fund based in Boston, MA. On 2026-02-12, the fund reported it's updated stock portfolio. In the 13F Holdings report, SILVERARC CAPITAL MANAGEMENT, LLC reported an equity portfolio of $720.1 Millions as of 31 Dec, 2025.

The top stock holdings of SILVERARC CAPITAL MANAGEMENT, LLC are , COGT, URGN. The fund has invested 7.9% of it's portfolio in ABIVAX SA and 6.1% of portfolio in COGENT BIOSCIENCES INC.

The fund managers got completely rid off AVIDITY BIOSCIENCES INC (RNA), AKERO THERAPEUTICS INC (AKRO) and CIDARA THERAPEUTICS INC (CDTX) stocks. They significantly reduced their stock positions in RAPPORT THERAPEUTICS INC, OLEMA PHARMACEUTICALS INC (OLMA) and UNIQURE NV (QURE). SILVERARC CAPITAL MANAGEMENT, LLC opened new stock positions in IMMUNOME INC (IMNM), PFIZER INC (PFE) and GUARDANT HEALTH INC (GH). The fund showed a lot of confidence in some stocks as they added substantially to CELCUITY INC (CELC), CENTESSA PHARMACEUTICALS PLC (CNTA) and BENITEC BIOPHARMA INC (BNTC).

SILVERARC CAPITAL MANAGEMENT, LLC Annual Return Estimates Vs S&P 500

Our best estimate is that SILVERARC CAPITAL MANAGEMENT, LLC made a return of 20.75% in the last quarter. In trailing 12 months, it's portfolio return was 53.51%.

Performance
S&P 500

New Buys

Ticker	$ Bought
immunome inc	24,191,000
pfizer inc	10,436,400
guardant health inc	9,388,100
spyre therapeutics inc	6,150,260
soleno therapeutics inc	5,439,560
fulcrum therapeutics inc	4,463,490
surrozen inc	3,555,500
relay therapeutics inc	3,368,490

New stocks bought by SILVERARC CAPITAL MANAGEMENT, LLC

Additions

Ticker	% Inc.
celcuity inc	322
centessa pharmaceuticals plc	224
benitec biopharma inc	164
contineum therapeutics inc	85.09
kalvista pharmaceuticals inc	78.02
praxis precision medicines i	61.03
cogent biosciences inc	52.78
veracyte inc	51.64

Additions to existing portfolio by SILVERARC CAPITAL MANAGEMENT, LLC

Reductions

Ticker	% Reduced
rapport therapeutics inc	-95.26
olema pharmaceuticals inc	-77.9
uniqure nv	-72.3
insmed inc	-65.52
rhythm pharmaceuticals inc	-63.26
compass therapeutics inc	-62.9
sionna therapeutics inc	-61.89
gossamer bio inc	-55.31

SILVERARC CAPITAL MANAGEMENT, LLC reduced stake in above stock

Sold off

Ticker	$ Sold
verastem inc	-9,207,540
avidity biosciences inc	-36,800,700
zura bio ltd	-3,119,560
camp4 therapeutics corp	-1,960,780
akero therapeutics inc	-30,559,800
modular med inc	-447,544
bridgebio oncology therapeut	-5,296,850
bicara therapeutics inc	-3,957,070

SILVERARC CAPITAL MANAGEMENT, LLC got rid off the above stocks

Sector Distribution

SILVERARC CAPITAL MANAGEMENT, LLC has about 76.4% of it's holdings in Healthcare sector.

Sector	%
Healthcare	76.4
Others	23.6

Market Cap. Distribution

SILVERARC CAPITAL MANAGEMENT, LLC has about 6.6% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
MID-CAP	35.2
SMALL-CAP	30.6
UNALLOCATED	23.3
LARGE-CAP	6.6
MICRO-CAP	3.5

Stocks belong to which Index?

About 59% of the stocks held by SILVERARC CAPITAL MANAGEMENT, LLC either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	55.6
Others	41
S&P 500	3.4

Top 5 Winners (%)		%
PRAX	praxis precision medicines i	198.3 %
COGT	cogent biosciences inc	97.2 %
OLMA	olema pharmaceuticals inc	94.8 %
GLUE	monte rosa therapeutics inc	79.2 %
KOD	kodiak sciences inc	69.4 %

Top 5 Winners ($)		$
	abivax sa	24.0 M
COGT	cogent biosciences inc	21.8 M
PRAX	praxis precision medicines i	16.2 M
KOD	kodiak sciences inc	11.7 M
CELC	celcuity inc	11.7 M

Top 5 Losers (%)		%
RCKT	rocket pharmaceuticals inc	-38.0 %
QURE	uniqure nv	-37.7 %
ORIC	oric pharmaceuticals inc	-25.0 %
AZYO	elutia inc	-21.8 %
TELA	tela bio inc	-20.3 %

Top 5 Losers ($)		$
QURE	uniqure nv	-10.0 M
ORIC	oric pharmaceuticals inc	-5.9 M
AMLX	amylyx pharmaceuticals inc	-0.9 M
TELA	tela bio inc	-0.8 M
CCCC	c4 therapeutics inc	-0.6 M

SILVERARC CAPITAL MANAGEMENT, LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of SILVERARC CAPITAL MANAGEMENT, LLC

SILVERARC CAPITAL MANAGEMENT, LLC has 64 stocks in it's portfolio. About 49.7% of the portfolio is in top 10 stocks. QURE proved to be the most loss making stock for the portfolio. was the most profitable stock for SILVERARC CAPITAL MANAGEMENT, LLC last quarter.

Last Reported on: 12 Feb, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ABEO	abeona therapeutics inc	0.46	627,738	3,308,180	reduced	-36.9

AGLE	spyre therapeutics inc	0.85	187,737	6,150,260	new

AKRO	akero therapeutics inc	0.00	0.00	0.00	sold off	-100

ALKS	alkermes plc	0.00	0.00	0.00	sold off	-100

AMLX	amylyx pharmaceuticals inc	0.85	506,242	6,115,400	reduced	-27.68

ARCT	arcturus therapeutics hldgs	0.00	0.00	0.00	sold off	-100

ASND	ascendis pharma a/s	1.46	49,228	10,497,400	reduced	-8.08

AVTX	avalo therapeutics inc	1.32	524,436	9,523,760	reduced	-27.25

AZYO	elutia inc	0.26	2,751,310	1,905,840	reduced	-3.5

BDSX	biodesix inc	0.00	0.00	0.00	sold off	-100

BIIB	biogen inc	1.84	75,412	13,271,800	reduced	-6.23

BNTC	benitec biopharma inc	1.37	731,717	9,856,230	added	164

CCCC	c4 therapeutics inc	0.53	1,994,220	3,808,970	added	5.1

CDTX	cidara therapeutics inc	0.00	0.00	0.00	sold off	-100

CELC	celcuity inc	5.20	375,132	37,415,700	added	322

CERS	cerus corp	0.80	2,814,380	5,797,630	added	3.63

CGEN	compugen ltd	0.74	3,479,800	5,324,100	added	5.09

CLDX	celldex therapeutics inc new	0.72	191,074	5,189,570	reduced	-45.24

CMPX	compass therapeutics inc	0.78	1,051,340	5,645,710	reduced	-62.9

CNTA	centessa pharmaceuticals plc	1.59	458,203	11,459,700	added	224